Mig-6 controls EGFR trafficking and suppresses gliomagenesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 15, 2010, Pages 6912-6917

  Ying, Haoqiang ^a   Zheng, Hongwu ^a   Scott, Kenneth ^a   Wiedemeyer, Ruprecht ^a   Yan, Haiyan ^a   Lim, Carol ^a   Huang, Joseph ^a   Dhakal, Sabin ^a   Ivanova, Elena ^a   Xiao, Yonghong ^a   Zhang, Hailei ^a   Hu, Jian ^a   Stommel, Jayne M ^a   Lee, Michelle A ^a   Chen, An Jou ^a   Paik, Ji Hye ^a   Segatto, Oreste ^b   Brennan, Cameron ^c   Elferink, Lisa A ^d   Wang, Y Alan ^a   Chin, Lynda ^a,e   DePinho, Ronald A ^a   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Glioblastoma; STX8; Vesicle

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN MIG 6; SNARE PROTEIN; SYNTAXIN; SYNTAXIN 8; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; EMBRYO; ENDOSOME; GENE DELETION; GENOMICS; GLIOBLASTOMA; GLIOMAGENESIS; HUMAN; HUMAN CELL; LYSOSOME; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BRAIN NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; LYSOSOMES; MICE; NEOPLASM INVASIVENESS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 77951061655     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914930107     Document Type: Article

References (44)

1. Furnari FB, et al. (2007) Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 21:2683-2710.
2. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
3. Parsons DW, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812.
4. Shinojima N, et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962-6970. (Pubitemid 37322983)
5. Huang PH, Xu AM, White FM (2009) Oncogenic EGFR signaling networks in glioma. Sci Signal 2:re6.
6. Chin L, Gray JW (2008) Translating insights from the cancer genome into clinical practice. Nature 452:553-563. (Pubitemid 351483369)
7. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
8. Fiorentino L, et al. (2000) Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol 20:7735-7750.
9. Makkinje A, et al. (2000) Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 275:17838-17847. (Pubitemid 30430836)
10. Pante G, et al. (2005) Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/ Met-induced cell migration and neurite growth. J Cell Biol 171:337-348. (Pubitemid 41540025)
11. Wick M, Bürger C, Funk M, Müller R (1995) Identification of a novel mitogen-inducible gene (mig-6): Regulation during G1 progression and differentiation. Exp Cell Res 219: 527-535.
12. Ferby I, et al. (2006) Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med 12:568-573.
13. Jeong JW, et al. (2009) Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci USA 106: 8677-8682.
14. Zhang YW, et al. (2007) Evidence that MIG-6 is a tumor-suppressor gene. Oncogene 26:269-276.
15. Prekeris R, Yang B, Oorschot V, Klumperman J, Scheller RH (1999) Differential roles of syntaxin 7 and syntaxin 8 in endosomal trafficking. Mol Biol Cell 10:3891-3908. (Pubitemid 29534033)
16. Subramaniam VN, et al. (2000) Preferential association of syntaxin 8 with the early endosome. J Cell Sci 113:997-1008.
17. Antonin W, et al. (2000) A SNARE complex mediating fusion of late endosomes defines conserved properties of SNARE structure and function. EMBO J 19:6453-6464.
18. Bièche I, et al. (1993) Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 53:1990-1994. (Pubitemid 23145715)
19. Brodeur GM, Sekhon G, Goldstein MN (1977) Chromosomal aberrations in human neuroblastomas. Cancer 40:2256-2263.
20. Asano T, et al. (2004) The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23:8571-8580. (Pubitemid 39576463)
21. Kleer CG, Bryant BR, Giordano TJ, Sobel M, Merino MJ (2000) Genetic changes in chromosomes 1p and 17p in thyroid cancer progression. Endocr Pathol 11:137-143. (Pubitemid 30610123)
22. Moley JF, et al. (1992) Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res 52:770-774.
23. Mori N, et al. (1998) Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood 92:3405-3409. (Pubitemid 28492351)
24. Bagchi A, Mills AA (2008) The quest for the 1p36 tumor suppressor. Cancer Res 68: 2551-2556.
25. Kim RH, et al. (2005) DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7:263-273. (Pubitemid 40568685)
26. Nagakubo D, et al. (1997) DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231:509-513. (Pubitemid 27214343)
27. Vasseur S, et al. (2009) DJ-1/PARK7 is an important mediator of hypoxia-induced cellular responses. Proc Natl Acad Sci USA 106:1111-1116.
28. Zhang X, et al. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450:741-744. (Pubitemid 350207680)
29. Xu D, Makkinje A, Kyriakis JM (2005) Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function. J Biol Chem 280:2924-2933. (Pubitemid 40189402)
30. Anastasi S, et al. (2005) Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin. Oncogene 24:4540-4548. (Pubitemid 41032617)
31. Anastasi S, et al. (2003) Feedback inhibition by RALT controls signal output by the ErbB network. Oncogene 22:4221-4234. (Pubitemid 36876243)
32. Nishikawa R, et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91: 7727-7731. (Pubitemid 24238258)
33. Stoscheck CM, Carpenter G (1984) Down regulation of epidermal growth factor receptors: Direct demonstration of receptor degradation in human fibroblasts. J Cell Biol 98:1048-1053.
34. Wells A, et al. (1990) Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 247:962-964. (Pubitemid 20081660)
35. Grandal MV, et al. (2007) EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 28:1408-1417.
36. Han W, Zhang T, Yu H, Foulke JG, Tang CK (2006) Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther 5:1361-1368. (Pubitemid 44772265)
37. Stoorvogel W, Strous GJ, Geuze HJ, Oorschot V, Schwartz AL (1991) Late endosomes derive from early endosomes by maturation. Cell 65:417-427. (Pubitemid 121002051)
38. Masui H, Wells A, Lazar CS, Rosenfeld MG, Gill GN (1991) Enhanced tumorigenesis of NR6 cells which express non-down-regulating epidermal growth factor receptors. Cancer Res 51:6170-6175.
39. Mosesson Y, Mills GB, Yarden Y (2008) Derailed endocytosis: An emerging feature of cancer. Nat Rev Cancer 8:835-850.
40. Luwor RB, et al. (2004) The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 23:6095-6104.
41. Stommel JM, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290.
42. Friedman LM, et al. (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc Natl Acad Sci USA 102:1915-1920.
43. Bachoo RM, et al. (2002) Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-277.
44. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890-902.